雅各臣科研制药以1.1亿元收购品牌中药业务43%股权

  雅各臣科研制药(02633-HK)公布该公司间接全资附属公司Sampan Development Limited以1.1338亿元收购Orizen Capital Limited 43%股权Orizen Capital Limited 主要从事品牌中药业务

Be the first to comment

Leave a Reply

Your email address will not be published.


*